Predictive factors of diabetic complications: A possible link between family history of diabetes and diabetic retinopathy

Journal of Diabetes and Metabolic Disorders

Volumn 13, Issue 1, 2014, Pages

  Maghbooli, Zhila ^a   Pasalar, Parvin ^b   Keshtkar, Abbasali ^a   Farzadfar, Farshad ^a   Larijani, Bagher ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Diabetic retinopathy; Epigenetic; Family history of diabetes

Indexed keywords

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE DURATION; DYSLIPIDEMIA; FAMILY HISTORY; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; OBESITY; ONSET AGE; PREDICTION; RETINA EXAMINATION; RISK ASSESSMENT; RISK FACTOR;

EID: 84908133424     PISSN: None     EISSN: 22516581     Source Type: Journal    
DOI: 10.1186/2251-6581-13-55     Document Type: Article

References (35)

1. Ceriello A, Ihnat MA, Thorpe JE. The " Metabolic Memory": is more than just tight glucose control necessary to prevent diabetic complications?. J Clin Endocrinol Metab 2009, 94:410-415. 10.1210/jc.2008-1824, 19066300.
2. Keenan HA, Costacou T, Sun JK, Doria A, Cavellerano J, Orchard TJ, Aiello LP, King GL. Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the 50-year medalist study. Diabetes Care 2007, 30(8):1995-1997. 10.2337/dc06-2222, 17507696.
3. Fong DS, Aiello LP, Ferris FL, Klein R. Diabetic retinopathy. Diabetes Care 2004, 27:2540-2553. 10.2337/diacare.27.10.2540, 15451934.
4. Harris MI, Klein R, Welbom TA, Knutman MW. Onset of NIDDM occurs at least 4-7 year before clinical diagnosis. Diabetes Care 1992, 15:815-819. 10.2337/diacare.15.7.815, 1516497.
5. Williams WW, Salem RM, McKnight AJ, Sandholm N, Forsblom C, Taylor A, Guiducci C, McAteer JB, McKay GL, Isakova T, Brennan EP, Sadlier DM, Palmer C, Söderlund J, Fagerholm E, Harjutsalo V, Lithovius R, Gordin D, Hietala K, Kytö J, Parkkonen M, Rosengård-Bärlund M, Thorn L, Syreeni A, Tolonen N, Saraheimo M, Wadén J, Pitkäniemi J, Sarti C, Tuomilehto J, et al. Association testing of previously reported variants in a large case-control meta-analysis of diabetic nephropathy. Diabetes 2012, 61(8):2187-2194. 10.2337/db11-0751, 3402313, 22721967.
6. Looker HC, Nelson RG, Chew E, Klein BE, Knowler WC, Hanson RL, et al. Genome-wide linkage analyses to identify loci for diabetic retinopathy. Diabetes 2007, 56(4):1160-1166. 10.2337/db06-1299, 17395753.
7. Hallman DM, Boerwinkle E, Gonzale VH, Klein BE, Klein R, Hanis CL. A genome-wide linkage scan for diabetic retinopathy susceptibility genes in Mexican Americans with type 2 diabetes from Starr County, Texas. Diabetes 2007, 56(4):1167-1173. 10.2337/db06-1373, 17251272.
8. Torres JM, Cox NJ, Philipson LH. Genome wide association studies for diabetes: perspective on results and challenges. Pediatr Diabetes 2013, 14:90-96. 10.1111/pedi.12015, 23350725.
9. Donaghue KC, Margan SH, Chan AK, Holloway B, Silink M, Rangel T, Bennetts B. The association of aldose reductase gene (AKR1B1) polymorphisms with diabetic neuropathy in adolescents. Diabet Med 2005, 22:1315-1320. 10.1111/j.1464-5491.2005.01631.x, 16176189.
10. Ma J, Li Y, Zhou F, Xu X, Guo G, Qu Y. Meta-analysis of association between the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ2 gene and diabetic retinopathy in Caucasians and Asians. Mol Vis 2012, 18:2352-2360. 3444298, 22993484.
11. Murea M, Ma L, Freedman BI. Genetic and environmental factors associated with type 2 diabetes and diabetic vascular complications. Rev Diabet Stud 2012, 9(1):6-22. 10.1900/RDS.2012.9.6, 3448170, 22972441.
12. Patel CJ, Chen R, Kodama K, Ioannidis JP, Butte AJ. Systematic identification of interaction effects between genome- and environment-wide associations in type 2 diabetes mellitus. Hum Genet 2013, 132(5):495-508. 10.1007/s00439-012-1258-z, 3625410, 23334806.
13. Sobrin L, Green T, Sim X, Jensen RA, Tai ES, Tay WT, Wang JJ, Mitchell P, Sandholm N, Liu Y, Hietala K, Iyengar SK, Brooks M, Buraczynska M, Van Zuydam N, Smith AV, Gudnason V, Doney AS, Morris AD, Leese GP, Palmer CN, Swaroop A, Taylor HA, Jr Wilson JG, Penman A, Chen CJ, Groop PH, et al. Family Investigation of Nephropathy Candidate gene association study for diabetic retinopathy in persons with type 2 diabetes: the Candidate gene Association Resource (CARe). Invest Ophthalmol Vis Sci 2011, 52(10):7593-7602. 10.1167/iovs.11-7510, 3183981, 21873659, Family Investigation of Nephropathy.
14. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, Collins FS, Manolio TA, et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A 2009, 106:9362-9367. 10.1073/pnas.0903103106, 2687147, 19474294.
15. Visscher PM, Brown MA, McCarthy MI, Yang J. Five years of GWAS discovery. Am J Hum Genet 2012, 90:7-24. 10.1016/j.ajhg.2011.11.029, 3257326, 22243964.
16. Standards of medical care in diabetesd 2012. Diabetescare 2012, 35((suppl 1)S11-S63).
17. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA 2007, 298:902-916. 10.1001/jama.298.8.902, 17712074.
18. International Diabetes Federation The Diabetes Atlas 2009, 4, International Diabetes Federation.
19. The diabetes control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329(14):977-986. The diabetes control and Complications Trial Research Group.
20. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998, 352(9131):837-853. UK Prospective Diabetes Study (UKPDS) Group.
21. Hirsch IB, Brownless M. Beyond hemoglobin A1c-need for additional markers of risk for diabetic microvascular complications. JAMA 2010, 303(22):2291-2292. 10.1001/jama.2010.785, 20530784.
22. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN, . DCCT/EDIC Reseach Group Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial-revisited. Diabetes 2008, 57(4):995-1001. 10.2337/db07-1618, 18223010, DCCT/EDIC Reseach Group.
23. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med 2012, 366(13):1227-1239. 10.1056/NEJMra1005073, 22455417.
24. Arar NH, Freedman BI, Adler SG, Iyengar SK, Chew EY, Davis MD, Satko SG, Bowden DW, Duggirala R, Elston RC, Guo X, Hanson RL, Igo RP, Jr Ipp E, Kimmel PL, Knowler WC, Molineros J, Nelson RG, Pahl MV, Quade SR, Rasooly RS, Rotter JI, Saad MF, Scavini M, Schelling JR, Sedor JR, Shah VO, Zager PG, Abboud HE, . Family Investigation of Nephropathy and Diabetes Research Group Heritability of the severity of diabetic retinopathy: the FIND-Eye study. Invest Ophthalomol Vis Sci 2008, 49(9):3839-3845. Family Investigation of Nephropathy and Diabetes Research Group.
25. Rema M, Saravana G, Deepa R, Mohan V. Familial clustering of diabetic retinopathy in South Indian Type 2 diabetic patients. Diabet Med 2002, 19(11):910-916. 10.1046/j.1464-5491.2002.00820.x, 12421427.
26. The Diabetes Control and Complications Trial Research Group Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. Diabetes 1997, 46(11):1829-1839. The Diabetes Control and Complications Trial Research Group.
27. Warpeha KM, Chakravarthy U. Molecular genetics of microvascular disease in diabetic retinopathy. Eye 2003, 17:305-311. 10.1038/sj.eye.6700348, 12724690.
28. Liew G, Klein R, Wong TY. The role of genetics in susceptibility to diabetic retinopathy. Int Ophthalmol Clin 2009, 49(2):35-52.
29. Eichler EE, Flint J, Gibson G, Kong A, Leal SM, Moore JH, Nadeau JH. Missing heritability and strategies for finding the underlying causes of complex disease. Nat Rev Genet 2010, 11:446-450. 10.1038/nrg2809, 2942068, 20479774.
30. Reddy MA, Natarajan R. Epigenetic mechanisms in diabetic vascular complications. Cardiovasc Res 2011, 90(3):421-429. 10.1093/cvr/cvr024, 3096305, 21266525.
31. Villeneuve LM, Natarajan R. The role of epigenetic in the pathology of diabetic complications. Am J Physiol Renal Physiol 2010, 299(1):F14-F25. 10.1152/ajprenal.00200.2010, 2904177, 20462972.
32. Zhang L, Chen B, Tang L. Metabolic memory: mechanisms and implications for diabetic retinopathy. Diabetes Res Clin Pract 2012, 96:286-293. 10.1016/j.diabres.2011.12.006, 22209677.
33. Siebel AL, Fernandez AZ, El-Osta A. Glycemic memory associated epigenetic changes. Biochem Pharmacol 2010, 80:1853-1859. 10.1016/j.bcp.2010.06.005, 20599797.
34. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B, . Diabetes Control Complications Trial/Epidemiology of Diabetes, Interventions and Complications Study Research Group Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2010, 353:2643-2653. Diabetes Control Complications Trial/Epidemiology of Diabetes, Interventions and Complications Study Research Group.
35. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1565-1576. 10.1056/NEJMoa0806359, 18784091.